Given the widespread immunity to MeV in the general population and the desirability of systemic administration as an approach for the treatment of metastatic cancer there may be significant advantages if this viral platform could be engineered to evade serum neutralization.
← all excerpts
MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
1
—
—